An Outpatient, Dose-Intense, Intravenous Cisplatin and Oral Etoposide Regimen for the Treatment of Advanced, Platinum-Resistant Ovarian Cancer

International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
Robert D MorganGordon C Jayson

Abstract

Advanced-stage, platinum-resistant, ovarian cancer can be treated with dose-intense chemotherapy; one such regimen includes intravenous cisplatin and oral etoposide. To minimize the toxicity associated with weekly cisplatin, pretreatment and posttreatment hydration is required, often necessitating inpatient, overnight admission. We report a shorter, within-day regimen for delivering weekly cisplatin. This was a retrospective study to assess the use of standard (inpatient; treatment time of 12 hours) versus modified (outpatient; treatment time of 4 hours) regimens. The primary outcome included all-grade and grade 3/4 adverse events. Secondary outcomes included clinical benefit response and, median progression-free survival and overall survival. Between January 2012 and December 2014, 66 women with metastatic ovarian cancer received dose-intense weekly cisplatin and oral etoposide (n = 45 standard, n = 21 modified). The commonest all-grade adverse events were anemia (96% vs 90%, standard and modified, respectively), fatigue (73% vs 67%), neutropenia (71% vs 76%), hypocalcemia (51% vs 43%), and thrombocytopenia (49% vs 57%). There were no statistically significant differences in the incidence or grades of adverse events. The clini...Continue Reading

References

Feb 15, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T MeyerG J Rustin
Feb 22, 2002·British Journal of Cancer·M E L van der BurgJ Verweij
Dec 24, 2010·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Richard Wyn GriffithsJurjees Hasan
Dec 30, 2011·The New England Journal of Medicine·Robert A BurgerUNKNOWN Gynecologic Oncology Group
Mar 29, 2012·The New England Journal of Medicine·Jonathan LedermannUrsula Matulonis
Mar 19, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric Pujade-LauraineIsabelle Ray-Coquard
Apr 29, 2014·Lancet·Gordon C JaysonJonathan A Ledermann

❮ Previous
Next ❯

Citations

Jan 25, 2019·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Robert D MorganGordon C Jayson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.